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1. Introduction
  Toxoplasmosis and rubella are two benign diseases 
when they affect adults or children. Primary infections 
with Toxoplasma gondii (T. gondii) and rubella initially 
unapparent or asymptomatic and lead to serious 
complications in pregnant women[1].
  Congenital infections with T. gondii and rubella are a 
significant cause of neonatal mortality and infant morbidity 
in the world[2]. 
  Recent studies have estimated that more than one third 
of the world population is infected with toxoplasmosis[3,4]. 
In developed countries, congenital toxoplasmosis affects 
0.01% and 0.1% of infants[5,6]. 
  In West Africa, T. gondii seroprevalence of 78% and 
53.6% have been reported in pregnant women from Nigeria 
and Benin, respectively[7,8]. The prevalence of T. gondii 
infection is linked to socio-economic situation in several 
studies[9]. 
  Despite WHO recommendations on rubella vaccination 
coverage, the infection has not been completely eradicated. 
In case of rubella infection during the first trimester of the 
pregnancy, the risk of congenital malformations of the fetus 
is 90%. In many countries, rubella seropositivity ranging 
between 54.1% and 95.2% has been reported among women 
of childbearing age[10].
  Due to the non-specificity of clinical symptoms and the 
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importance of early recognition of in utero infection, the 
serological screening of T. gondii and rubella is based on 
IgG and IgM detection. The absence of T. gondii and rubella 
anti-IgG before or during the first trimester of pregnancy 
identifies women at risk for infection and congenital 
transmission [6].
  In Burkina Faso, as in most of sub-Saharan Africa, 
toxoplasmosis and rubella are not routinely screened in 
pregnant women and little data on these two infections is 
available.
  This retrospective study aimed to determine the 
seroprevalence of toxoplasmosis and rubella among pregnant 
women attending antenatal private clinic at Ouagadougou in 
Burkina Faso.
2. Material and methods
2.1. Patients
  This retrospective study was conducted from February 2006 
to June 2009 and 182 pregnant women attending antenatal 
clinics during the first trimester of their pregnancy were 
included. They were referred to the gynecological service of 
the private clinic Moussa Kone by different socio-medical 
centres of Ouagadougou.
2.2. Rubella and toxoplasma serology
  All patient sera were tested for rubella and toxoplasmosis 
anti-IgG using commercial ELISA kits (PlateliaTM Rubella 
IgG and Platelia™ Toxo IgG. BIO-RAD, Marnes la Coquette. 
France). These are solid-phase enzyme immunoassays for 
the qualitative and quantitative detection of IgG antibodies 
against rubella and toxoplasmosis in human serum. The 
presence and amount of anti-rubella and anti-toxoplasmosis 
IgG in sera were determined by comparing the optical 
density of samples to be tested with a standard. Antibody 
levels obtained were expressed in International Units per mL 
(IU/mL).
  The presence of anti-rubella and anti-toxoplasmosis 
IgM in serum samples was tested using commercial ELISA 
kits Platelia Rubella IgM and Platelia Toxo IgM (BIO-RAD. 
Marnes la Coquette. France) following the manufacturer’s 
instructions.
  The study was approved by the Joint Saint Camille/CERBA 
Ethics Committee. Individual informed consent was obtained 
from all pregnant women.
2.3 Statistical analysis
  Data analysis was done by Statistical Package for the Social 
Sciences (SPSS version 17.0) and Epi Info 6.4. The results 
were considered significant for P < 0.05.
3. Results
  One hundred eighty two (182) women were tested for 
toxoplasmosis serology (IgM and IgG) and one hundred 
(100) for rubella serology (IgM and IgG). Women included 
were aged 18 years or above and had been referred for 
Table 1





IgG IgM IgG IgM
Positive Negative Positive Negative Positive Negative Positive Negative
Age group (year)
18-25   29 10 (34.5)   19 (65.5)   5 (17.2)  24 (82.8)    13 11 (84.6)   2 (15.4) 0 (0.0)   13 (100.0)
26-35 109 19 (17.4)   90 (82.6) 0 (0.0)   109 (100.0)    61 49 (80.3) 13 (19.7) 1 (1.6) 60 (98.4)
36-50   44    8 (18.2)   36 (81.8) 2 (4.5)   42 (95.5)   26 17 (65.4)   9 (34.6) 0 (0.0)   26 (100.0)
Total 182 37 (20.3) 145 (79.7) 7 (3.8) 175 (96.2) 100 77 (77.0) 24 (23.8) 1 (1.0) 99 (99.0)
Year of the test
2006   49 16 (32.7)   33 (67.3)   6 (12.2) 43 (87.8)  26 22 (84.6)   4 (15.4) 0 (0.0)   25 (100.0)
2007   55 11 (20.0)   44 (80.0) 0 (0.0)   55 (100.0)  28 24 (85.7)   4 (14.3) 1 (3.6) 27 (96.4)
2008   33   4 (12.1)   31 (87.9) 0 (0.0)   33 (100.0)  20 13 (65.0)    7 (35 .0) 0 (0.0)   20 (100.0)
2009   43   6 (14.0)   37 (86.0) 1 (2.3) 42 (97.7)  27 18 (66.7) 11 (33.3) 0 (0.0)   27 (100.0)
 
Table 2
Toxoplasmosis and rubella antibodies titers among pregnant women (IU/mL). 
Characteristics
Age group (years)
Anti-T. gondii IgG Anti-rubella IgG 
Number Mean依SD Number Mean依SD
18-25   29 223.7依86.1 13 252.9依280.4
26-35 109 152.2依50.4 61 175.3依177.1
36-50   44   69.0依28.5 26 124.8依138.9
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prenatal care at the clinic Moussa Kone from 2006 to 2009. 
The majority of women tested for toxoplasmosis (59.9%) and 
rubella (61.0%) were within the age group of 26-35 years. The 
large proportion of Toxoplasma serology (57.8%) and rubella 
(54.0%) was required between 2006 and 2007.
3.1. Toxoplasmosis and rubella seropositivity
  Among the 182 women included in the study, 37 (20.3%) 
were positive for anti-T. gondii IgG and seven samples 
(3.8%) were positive for anti-toxoplasmosis IgM. Of the 100 
pregnant women tested for rubella. 77 (77.0%) were positive 
for anti-rubella IgG while only one woman was positive for 
IgM (Table 1). Each year, an average of 45 pregnant women 
were tested for toxoplasmosis and rubella serology in 2006 to 
2009 (Table 1). 
  Pregnant women in the age group of 18-25 years showed 
the highest frequency of anti-toxoplasmosis (34.5%) 
and anti-rubella IgG (84.6%) (Table 1). The rate of anti-
toxoplasmosis IgG was significantly higher among pregnant 
women aged 18-25 years compared to the 26-35 years group 
(P = 0.044). The prevalence of anti-Toxoplasma and anti-
rubella IgG decreased between 2006 and 2008 from 32.7% to 
12.1% and 84.6% to 65.0%, respectively (Table 1).
 
3.2. Antibody titer to T. gondii and rubella in pregnant 
women
  As shown in Table 2, means titers of anti-rubella and 
toxoplasmosis IgG were calculated among pregnant women 
(Table 2). The mean values of anti-toxoplasmosis IgG were 
(223.7依86.1), (152.2依50.4) and (69.0依28.5) IU/mL in age groups 
18-25; 26-35 and 36-50 years, respectively. There was no 
significant difference in the mean titer of anti-toxoplasmosis 
IgG between the three age groups. The mean titer of anti-
rubella IgG was higher among women aged 18-25 years 
with (252.9依280.4) IU/mL. But this titer was not significantly 
higher than that of other groups.
4. Discussion 
  In developed countries, toxoplasmosis and rubella 
screening is part of the health tests included in the prenatal 
assessment. Toxoplasmosis contracted during the first 
trimester of pregnancy is responsible for spontaneous 
abortions, stillbirth or severe illness in more than 25% of 
pregnant women.
  Despite the existence of an effective vaccine, infection due 
to rubella virus is not eradicated. Epidemics occur at regular 
intervals in the world. 
  The aim of this retrospective study was to determine 
the seroprevalence of toxoplasmosis and rubella among 
pregnant women during the first trimester of pregnancy and 
to assess the potential risk of congenital transmission of 
these diseases in Burkina Faso. 
  From the total of 182 sera of pregnant women 37 (20.3%) 
and 7 (3.8%) were reactive for anti-toxoplasma IgG and IgM, 
respectively. 
  The prevalence of anti-toxoplasma antibodies found in this 
study is lower than that found in most developed countries: 
43.8% in France[11] and in Africa: 75.4% in Nigeria[7]; 
53.6% in Benin [8]; 40.2% in Dakar, Senegal[12]; and 34.1% 
from pregnant women in Sudan[13]. It is comparable to the 
prevalence found by Simpore et al in Burkina Faso[14]. 
However, it is higher than the prevalence of 12.8% observed 
among pregnant women in South Africa[15]. In developed 
countries, toxoplasmosis and rubella screening is part 
of the health tests included in the prenatal assessment. 
Toxoplasmosis contracted during the first trimester of 
pregnancy is responsible for spontaneous abortions, stillbirth 
or severe illness in more than 25% of pregnant women.
  In our study, the prevalence of rubella IgG was 77% and 
only one woman carried anti-rubella IgM. This prevalence 
of rubella is lower than the prevalence of 95.3% and 97.9% 
found in Mozambique[16] and Nigeria[17], respectively.  
  The prevalence of rubella in pregnant women in Burkina 
Faso is higher than the 0.42% of prevalence found in 
childbearing age women in Turkey[18].
  We found a high proportion of non-immune pregnant 
women who are at risk of contracting toxoplasmosis (65.5%) 
and rubella (15.4%) in the third trimester of pregnancy, 
especially in the age group of 18-25 years. 
  Toxoplasma (57.8%) and rubella (54.0%) serologies have 
been mostly requested in 2006 and 2007. Few women seek 
toxoplasmosis and rubella serologies during pregnancy in 
Burkina Faso. This could be due to the relatively high cost 
of these two tests (the cost is approximatively 32 Euros) for 
predominantly low-income populations.
  In most of sub-Saharan countries, the efforts of health 
authorities are focused on sexually transmitted diseases 
such as HIV. Diseases such as toxoplasmosis and rubella are 
neglected. 
  Although there is an effective vaccine against rubella, 
immunization coverage is low and affects only 48% of the 
population in developing countries[19,20]. Toxoplasmosis and 
rubella diagnosis should be systematic in Burkina Faso, 
because of the existence of a strong agro-pastoral activity 
especially in rural areas, which increases the spread of 
zoonotic diseases[21]. Indeed, previous studies have shown 
that the coexistence between humans and animals may be a 
contributing factor raising these zoonotic infections[3, 21]. 
  Meat and milk are important dietary components for the 
majority of the population in Burkina Faso. A study in Brazil [3]
showed that frequent consumption of poultry (chicken), fruit 
juice manufactured locally and vegetables washed with 
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untreated water was significantly associated with T. gondii 
infection in pregnant women. However, contamination of 
water by oocytes could be the most likely source of infection 
with toxoplasmosis and rubella in Burkina Faso.
  The diagnosis of toxoplasmosis and rubella is necessary 
in pregnant women in Burkina Faso because of the low 
immunization coverage rate of rubella and the high level of 
exposure to these two infections which can be harmful to the 
newborn if contracted by women before the third trimester of 
pregnancy. 
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